González LCA, García RJ, Castillo SJJ, Arámbula MHA, García RRU, Chávez GE

Language: Spanish
References: 15
Page: 614--620
PDF size: 464.50 Kb.

ABSTRACT

Background: Miller-Fisher syndrome is a rare variant of Guillain-Barre syndrome. The diagnosis is stablished mainly based on clinical history and physical exploration; the confirmation needs a positive serology for anti-GQ1b antibodies. Usually, it is a self-limited disease.
Clinical case: A 19-year-old male patient who, after food intoxication, developed dermatosis (urticaria) and 48 hours later complained about neurological symptoms (diplopia, blurred vision, bilateral mydriasis) besides the triad of ophthalmoplegia, ataxia, and areflexia, so Miller-Fisher syndrome was suspected. The diagnosis was confirmed as serologically positive for antibodies anti-GQ1b. The patient was successfully treated with intravenous immunoglobulin.
Conclusions: Although the clinical course of Miller-Fisher syndrome is considered of spontaneous relief, timely treatment prevents complications and accelerates symptom relief.

REFERENCES

1. Fisher CM. An unusual variant of acute idiopathic polyneuritis(syndrome of ophthalmoplegia, ataxia and areflexia)N Engl J Med 1956; 255 (2): 57-65. doi: 10.1056/NEJM195607122550201

2. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinicalfeatures and prognosis of Miller Fisher Syndrome. Neurology2001; 56 (8): 1104-1106. doi: 10.1212/wnl.56.8.1104

3. Domínguez-Moreno R, Tolosa-Tort P, Patiño-Tamez A, Quintero-Bauman A, et al. Mortalidad asociada al diagnósticode síndrome de Guillain-Barré en adultos ingresados eninstituciones del sistema sanitario mexicano.Rev Neurol2014; 58 (1): 4-10. doi: 10.33588/rn.5801.2013370

4. De la O-Peña D, Robles-Figueroa M, Chavez-Peña Q,Bedolla-Barajas M. Características del síndrome de Guillain-Barré en adultos: resultados de un hospital universitario.Rev Med Inst Mex Seguro Soc 2015; 53 (6): 678-85.

5. Lo YL. Clinical and immunological spectrum of the MillerFisher syndrome. Muscle Nerve 2007; 36: 615-627. doi:10.1002/mus.20835

6. Snyder LA, Rismondo V, Miller NR. The Fisher variant of Guillain-Barre syndrome (Fisher syndrome). J Neuro-Opthalmol2009; 29: 312-324. doi: 10.1097/WNO.0b013e3181c2514b

7. Berlit P, Rakicky J. The Miller Fisher syndrome. Review ofthe literature. J Clin Neuroothalmol 1992; 12 (1): 57-63.

8. Littlewood R, Bajada S. Successful plasmapheresis in theMiller-Fisher syndrome. BMJ 1981; 282: 778 doi: 10.1136/bmj.282.6266.778

9. Zifko U, Drlicek M, Senautka G, Grisold W. High doseimmunoglobulin therapy is effective in the Miller Fishersyndrome. J Neurol 1994; 241: 178-179. doi: 10.1007/BF00868348

10. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenousimmunoglobulin therapy for Miller Fisher syndrome.Neurology 2007; 68 (14): 1144-1146. doi: 10.1212/01.wnl.0000258673.31824.61

11. Willison HJ, O’Hanlon GM. The Immunopathogenesis ofMiller Fisher syndrome. J Neuroimmunol 1999; 100: 3-12doi: 10.1016/s0165-5728(99)00213-1

12. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgGantibody to ganglioside GQ1b is a possible marker of MillerFisher syndrome. Ann Neurol 1992; 31 (6): 677-679 doi:10.1002/ana.410310619

13. Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibodysyndrome: clinical and immunological range. J NeurolNeurosurg Psychiatry 2001; 70: 50-55. doi: 10.1136/jnnp.70.1.50

14. Yepishin IV, Allison RZ, Kaminskas DA, Zagorski NM,Liow KK. Miller Fisher syndrome: A case report highlightingheterogeneity of clinical features and focuseddifferential diagnosis. Hawaii J Med Public Health 2016;75 (7): 196-9.

15. Rebolledo-García D, González-Vargas PO, Salgado-CalderónI. Síndrome de Guillain-Barré: viejos y nuevos conceptos.Med Int Méx 2018; 34 (1): 72-81. doi: 10.24245/mim.v34i1.1922